Jianpi Huazhuo Xiaoying Decoction plus emotional conditioning for thyroid nodule treatment: Impact on treatment outcomes and anxiety/depression

Figure 1 Flowchart of patient inclusion and exclusion screening process.

Figure 2 Pulsatility index and resistance index comparisons (control vs observation group). A: Pre-treatment and post-treatment pulsatility index measurements; B: Pre-treatment and post-treatment resistance index measurements. ^aP < 0.05, ^bP < 0.01 (intragroup differences from baseline); ^cP < 0.05 (intergroup differences at identical time points). PI: Pulsatility index; RI: Resistance index.

Figure 3 Thyroid function comparisons between control and observation groups. A: Free triiodothyronine measurements pre-treatment and post-treatment; B: Free thyroxine measurements pre-treatment and post-treatment; C: Thyroid-stimulating hormone measurements pre-treatment and post-treatment. ^aP < 0.05, ^bP < 0.01 (significant within-group changes from baseline); ^cP < 0.05 (between-group differences at matched timepoints). FT3: Free triiodothyronine; FT4: Free thyroxine; TSH: Thyroid-stimulating hormone.

Figure 4 Thyroid autoantibody levels in control and observation groups. A: Thyroid peroxidase antibody measurements pre-treatment and post-treatment; B: Thyroglobulin antibody measurements pre-treatment and post-treatment. ^aP < 0.05, ^bP < 0.01 (intragroup differences from baseline); ^cP < 0.05 (intergroup differences at matched time intervals). TPoAb: Thyroid peroxidase antibody; TgAb: Thyroglobulin antibody.